Read Article

Supporting international business matching, LSMIP propritizes "Speed" and "Accuracy" in out service.
Please be noted that contents are in English/Japanese, translated on a request basis from authors/members.



Next-generation TCR/BCR repertoire analysis & Neoepitope Analysis

  • Target market
    Japan, USA, Other countries
  • Business category
  • Business function
    Clinical development > Data management, Regulatory > New Drug Application, Regulatory > Pharmacovigilance, Engineering, production, GMP > CDMO selection, Business consulting > Licensing
  • Keyword
  • Author
    "Eiichi Yamaguchi, Ph.D." of "Repertoire Genesis Inc. / レパトア・ジェネシス株式会社"
  • Availability


  Repertoire Genesis, Inc is a biotech company providing a next-generation TCR/BCR repertoire analysis with unbiased PCR and novel bioinformatics software originally developed by us. This technology makes it possible to accurately evaluate diversity and specify for evaluation of treatment effects by cancer immune cell therapy, bone marrow transplantation, or immune check point inhibitors. Our platform technologies can be used for development of promising advanced medical technologies such as TCR gene therapy, CAR-T therapy, antibody drug development, and immune cell therapy with neoantigen.
  • 1

Comments (Require approval)

What information are you looking for in articles?
Let us help you to find out the articles for your business requirements!
Like many other companies, we use cookies and other technologies, some of which are essential to make our website work. By clicking Accept or continuing to use our site, you agree to use these cookies and other technologies. To learn more, check out our privacy policy.